At Vyriad, we are developing the next generation of targeted genetic therapies by engineering viruses, viral vectors and viral envelope glycoproteins to deliver genes directly to targeted cells. This targeting technology facilitates oncolytic virotherapy, in vivo gene therapies and gene editing applications.
We are testing our oncolytic viruses as monotherapies and in combination with immuno-oncology drugs.
Phase 1-2 Clinical Studies are currently active in:
Non-small cell lung cancer
Squamous cell carcinoma of the head and neck
Metastatic colorectal cancer
Breast cancer
Bladder cancer
Other cancer types
Vyriad has clinical research collaboration agreements with Regeneron, Mayo Clinic, and other leading research and medical institutions.
-
Industry
-
Biotechnology
-
Company size
-
51-200 employees
-
Headquarters
-
Rochester, MN
-
Type
-
Privately Held
-
Founded
-
2015